Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $6.88 Consensus PT from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $6.8750.

A number of brokerages recently commented on SRTS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Alliance Global Partners initiated coverage on Sensus Healthcare in a report on Friday, March 6th. They set a “buy” rating and a $7.50 price objective for the company. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Maxim Group cut their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently made changes to their positions in the stock. Opes Wealth Management LLC purchased a new stake in shares of Sensus Healthcare during the third quarter worth $50,000. XTX Topco Ltd purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth $77,000. Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth $79,000. Mindset Wealth Management LLC raised its position in shares of Sensus Healthcare by 28.1% in the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after buying an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth $219,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Performance

SRTS stock opened at $2.71 on Wednesday. The stock has a 50-day moving average price of $3.56 and a 200-day moving average price of $4.02. Sensus Healthcare has a 1-year low of $2.66 and a 1-year high of $5.92. The firm has a market cap of $44.61 million, a PE ratio of -5.77 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The business had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.